Aurobindo pharma, Company

Puravankara reports highest ever sales for Q2 and for H1 of any financial year since inception.- Highest-ever sales for the second quarter and the first half of any financial year- H1FY23 saw sales value grow to Rs 1,300+ Cr- Recorded quarterly sales of Rs 791 crores, area sold stood at 1.07 msft during Q2FY23- Robust launch pipeline of upcoming projects of 15 msftCommenting on the company's performance, Ashish R Puravankara, Managing Director, Puravankara Limited, said, "We have achieved the highest-ever sales for the second quarter and the first half of any financial year. Construction milestones are being achieved every quarter. H1FY23 saw sales value grow to Rs 1,300+ Cr, compared to Rs 900+ Cr. for a similar period last year. Similarly, collections grew to Rs 925 Cr. vs Rs 620 Cr. for a similar period last year, implying an increase of almost 50 per cent. In Q2, our collections from residential sales grew by 52 per cent or Rs 518 Cr., compared to the same period last year at Rs 341 Cr. Sales have also increased by 33 per cent at Rs 791 Cr. compared to the same quarter one year ago at Rs 597 Cr. Both sales and collections have shown robust growth, and we are excited and happy with the performance. New launches in the next two quarters will strengthen the sales and the cash flow momentum. We are expecting to deliver over 1,500 units in the next 2 quarters." Operational Highlights for Q2FY23- Area sold stood at 1.07 msft up by 18 per cent, compared to 0.91 msft in the quarter ended Sept 30, 2022- Sales value stood at Rs 791 crore up by 33 per cent, compared to Rs 597 crore in the quarter ended Sept 30, 2022- Sale realization stood at Rs 7,396 up by 13 per cent, compared to Rs 6,556 in the quarter ended Sept 30, 2022Operational Highlights for H1FY23- Area sold stood at 1.75 msft up by 32 per cent, compared to 1.33 msft in the quarter ended Sept 30, 2022- Sales value stood at Rs 1,304 crore, up by 43 per cent compared to Rs 910 crore in the quarter ended Sept 30, 2022- Sale realization stood at Rs 7,454 up by 9 per cent, compared to Rs 6,845 in the half year ended Sept 30, 2022Consolidated Financial Performance (As per IND-AS 115) for the quarter ended 30th Sept 2022- Consolidated Revenues stood at Rs 252.85 crores- Profit (Loss) before Tax stood at Rs (22.10) Crore- Profit (Loss) After Tax stood at Rs (20.95) croresConsolidated Financial Performance (As per IND-AS 115) for the half-year ended 30th Sept 2022- Consolidated Revenues stood at Rs 550.20 crores- Profit before Tax stood at Rs 25.43 crores- Profit After Tax stood at Rs 13.72 croresCash FlowsCollections grew to Rs 925 crores vs Rs 620 crores for a similar period last year, implying an increase of almost 50 per cent. As on September 30, 2022, the balance collections from sold units in all launched projects stood at Rs 2,640 crores. The balance cost to be incurred stood at Rs 2,933 crores. Combined with the unsold receivables from launched projects of Rs 4,684 crores, the projected operating surplus of Rs 4,391 crores on the launched portfolio compares very favourably against the current outstanding net debt of Rs 2,144 crores. Besides this, we have not opened for sale inventory in existing projects with an estimated surplus of Rs 1,653 crores. DebtOur net debt stood at Rs 2,144 crores last Quarter and Net debt to equity ratio stood at 1.10 The weighted average cost of debt is 11.02 per cent as of September 30, 2022. Credit RatingICRA has reaffirmed rating to "A-" with stable Outlook. Outlook Although the outlook for the world economy has grown gloomier, India's economic development is still expected to grow, albeit with some deceleration. We believe India's real estate market is likely to maintain its current upward trend backed by the solid structural foundation and gain in demand. We are confident in continuing to add value for all our stakeholders by delivering growth and margin expansion through optimal utilization of capital. Upon transition to Indian Accounting Standards (Ind AS) including Ind AS 115, the Company had moved from the erstwhile percentage of completion method of revenue recognition to a completed contract method of revenue recognition. The aforesaid change in the timing of revenue recognition has brought a significant variation in the periodical financial results as the revenue is no longer recognised rateably over the project execution period but recognised upon completion of the project and handover of flats to the customers. Consequently, the financial results do not truly depict the Company's project execution and sales efforts on a periodical basis. The above accounting impact is very evident in our current period's financial results.DISCLAIMER:Some of the statements in this communication may be 'forward-looking statements within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the company's operations include changes in the industry structure, significant changes in the political and economic environment in India and overseas, tax laws, duties, litigation and labour relations.This story is provided by BusinessWire India.will not be responsible in any way for the content of this article. (ANI/BusinessWire India)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Aurobindo PharmaFOLLOW

Aurobindo pharma, Latest News

Refer Now & Earn Forever being its key feature Shareholders needs to be atleast 15 days old members of ... ...

ThoughtFocus, Inc. ('ThoughtFocus' or the 'Company'), a global provider of digital services and technology enabled digital operations for the financial services, manufacturing, and higher education sectors, is pleased to announce that H.I.G. Capital ...

Mr. Bharat Moossaddee Appoints industry veteran Mr.Bharat Moossaddee as Independent Director Q2 Revenue up 30% YOY Major breakthrough in ... ...

Dynamic Cables Limited (DCL), a Jaipur based power cable manufacturer announced its result for Q2FY23. Company reported a sale of Rs 173.4 crs, a healthy growth of 30% yoy. In the quarter gone by Company received major breakthrough in its MVCC produc ...

Aurobindo Pharma has posted a decline of 41 per cent in its net profit to Rs 409 crore in ... ...

Hyderabad, Nov 10 Aurobindo Pharma on Thursday clarified that the arrest of its Director P. Sarath Chandra Reddy ... ...

The Enforcement Directorate has arrested two businessmen belonging to Andhra Pradesh and Telangana in Delhi Excise Policy 2021-22 money ... ...

Puravankara reports highest ever sales for Q2 and for H1 of any financial year since inception. ...